Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Johnnycash23on Aug 22, 2023 4:58pm
145 Views
Post# 35600660

RE:RE:RE:RE:RE:RE:Something is cooking!!!

RE:RE:RE:RE:RE:RE:Something is cooking!!!

Look at the corporate presentation! Nothing is cooking! In the partnership section, there is not a single mention of that ever evasive Chinese company or anything at all. 

As for TH1902, "once the phase 1 has resumed...". No target date!

The Company probably has 15 million in cash left with 60 million in debt and a market cap below 30 million as of today. Who cares about the Ebitda if the company runs out of cash in 3 months! Look at my nice car... just can't afford tu put gas in it! 

Revenue guidance still down to 82-87 million from 90-95 million that was "confirmed" six months ago. Given their track record, they will hit or miss the low end of the bracket meaning that, without price increases, sales would be declining. 

It is as if even the orchestra has left the Titanic!

<< Previous
Bullboard Posts
Next >>